Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) issued its quarterly earnings results on Thursday, March, 16th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.02. View Catabasis Pharmaceuticals' Earnings History.

4 analysts have issued 12 month price objectives for Catabasis Pharmaceuticals' stock. Their forecasts range from $4.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $6.25 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.

Here are some recent quotes from research analysts about Catabasis Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (5/19/2017)
• 2. Wedbush analysts commented, " With numerical improvements in all function-associated endpoints observed in Part B of the MoveDMD trial, we believe extended treatment with edasalonexent (CAT-1004) could result in a deepening of the response'a potential positive sign that could boost shares. We continue to look to Q2:17 for an interim look of the MoveDMD study at 24 weeks (Part C) as the next material catalyst. Q4/FY16 Financial Update: CATB reported no revenues and GAAP EPS (loss) of $(0.47)/$(2.22) vs. consensus of $(0.49)/$(2.25). CATB ended 2016 with ~$38.5 million in cash and cash equivalents and we project runway through Q1:18, in line with company guidance." (3/20/2017)

Catabasis Pharmaceuticals saw a decline in short interest in April. As of April 13th, there was short interest totalling 1,288,297 shares, a decline of 25.1% from the March 31st total of 1,721,146 shares. Based on an average daily volume of 386,753 shares, the short-interest ratio is currently 3.3 days. Approximately 13.1% of the company's stock are short sold.

Some companies that are related to Catabasis Pharmaceuticals include CASI Pharmaceuticals (CASI), Galmed Pharmaceuticals Ltd (GLMD), Eiger Biopharmaceuticals (EIGR), Flex Pharma (FLKS), GTx (GTXI), Bioline RX Ltd (BLRX), Zosano Pharma Corp (ZSAN), Prima BioMed Ltd (PBMD), XOMA (XOMA), vTv Therapeutics (VTVT), TRACON Pharmaceuticals (TCON), Inotek Pharmaceuticals Corp (ITEK), OvaScience (OVAS), ADMA Biologics (ADMA), Medgenics (GNMX), Bellerophon Therapeutics (BLPH), Trillium Therapeutics (TRIL) and Biopharmx Corp (BPMX).

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Catabasis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SV Health Investors LLC (15.12%), Clarus Ventures LLC (14.56%), Sphera Funds Management LTD. (2.05%), Vanguard Group Inc. (1.95%), Oppenheimer & Co. Inc. (0.48%) and Renaissance Technologies LLC (0.35%). Company insiders that own Catabasis Pharmaceuticals stock include Medimmune Ventures, Inc and Nicholas Galakatos. View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Catabasis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Oppenheimer & Co. Inc., Renaissance Technologies LLC and Sphera Funds Management LTD.. Company insiders that have bought Catabasis Pharmaceuticals stock in the last two years include Medimmune Ventures, Inc and Nicholas Galakatos. View Insider Buying and Selling for Catabasis Pharmaceuticals.

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.36.